Latest Gastric inhibitory polypeptide Stories
Scientists from the Helmholtz Zentrum München (HMGU) and the Technische Universität München (TUM), together with scientists in the USA, have developed a new therapeutic approach for treatment of type 2 diabetes.
New research from the University of Cincinnati (UC) points to the naturally produced protein apolipoprotein A-IV (apoA-IV) as a potential target for a new diabetes therapeutic.
A study by Columbia researchers suggests that cells in the patient's intestine could be coaxed into making insulin, circumventing the need for a stem cell transplant.
The increasing prevalence of type 2 diabetes places a huge burden on its victims and poses a tremendous challenge to healthcare systems.
INDIANAPOLIS, Feb. 17 /PRNewswire/ -- Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP).
OSAKA, Japan, March 6 /PRNewswire/ -- Takeda Pharmaceutical Company Limited today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, was informed as part of regular discussions about the alogliptin New Drug Application (NDA) with the United States Food and Drug Administration (FDA), that although the alogliptin NDA was filed prior to issuance of FDA's December 2008 guidance on new Type 2 diabetes treatments, the FDA will apply...
OSAKA, Japan, Oct. 10 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.